CA-SHIFTLEFT
17.11.2021 09:02:09 CET | Business Wire | Press release
ShiftLeft, Inc ., an innovator in automated application security testing, today announced that its Chief Scientist, Fabian Yamaguchi, and Security Research Engineer, Claudiu-Vlad Ursache, will give a presentation focused on Ghidra2cpg at the No Hat Conference in Bergamo, Italy on November 20, 2021. The No Hat 2021 is a security conference organized to bring together specialists, professionals and hobbyists operating in the field of computer security and privacy.
Event Details:
Who:
Fabian Yamaguchi, Chief Scientist and Claudiu-Vlad Ursache, Security Research Engineer, ShiftLeft
What:
Virtual Session: Presentation on Ghidra2cpg: From graph queries to vulnerabilities in binary code
When:
Saturday, November 20, 2021, 11:15am – 12:00pm CET
Where:
Centro Congressi Giovanni XXIII - Bergamo, Italy
For more information, visit : https://www.nohat.it/program
Session Abstract - Ghidra2cpg: From graph queries to vulnerabilities in binary code
Uncovering bugs in source code is hard enough as it is, but when all you have is a binary, the importance of tooling becomes undeniable. Disassemblers such as IDA Pro, Ghidra, BinaryNinja or Radare2 provide a strong foundation for an investigation but are designed primarily to assist in what remains a manual investigation. This leaves room for partial automations that make the discovery process less painful.
Fabian and Claudiu were looking to design a search tool for binary code that allows them to uncover instances of programming patterns linked to vulnerabilities - at scale and for multiple major instruction sets. In this talk, they will present ghidra2cpg, an extension for the open-source code mining platform Joern that enables it to process binary code. Together, Joern and ghidra2cpg enable you to quickly uncover the attack surface, search for variants of known vulnerabilities, and gather information interactively using a query language.
In this session they will show how to write queries for the system that describe bugs in source code and introduce corresponding queries for binary code, highlighting what's harder and what is easier to describe when looking at the machine code directly. They will also be looking at modern consumer-grade router firmware and may drop a zero-day or two in the process.
About Fabian Yamaguchi
Fabian is Chief Scientist at ShiftLeft Inc and an Associate Professor Extraordinary at Stellenbosch University. He has over 15 years of experience in the security domain, where he has worked as a security consultant and researcher, focusing on manual and automated vulnerability discovery. Throughout his work, he has identified previously unknown vulnerabilities in popular system components and applications such as the Microsoft Windows kernel, the Linux kernel, the Squid proxy server, and the VLC media player. He has presented his findings and techniques at both major industry conferences such as BlackHat USA, DefCon, First, and CCC, and renowned academic security conferences such as ACSAC, Security and Privacy, and CCS. He holds a master’s degree in computer engineering from Technical University Berlin, as well as a PhD in computer science from the University of Goettingen.
About Claudiu-Vlad Ursache
Claudiu-Vlad Ursache is a Security Research Engineer at ShiftLeft, having recently entered cybersecurity after a decade of writing software. In his day-to-day job he builds static analysis tools and his current research focuses on IoT firmware.
About ShiftLeft
ShiftLeft enables software developers and application security teams to radically reduce the attackability of their applications by providing near-instantaneous security feedback on software code during every pull request. By analyzing application context and data flows in near real-time with industry leading accuracy, ShiftLeft empowers developers and appsec team to find and fix the most serious vulnerabilities faster. Using its patented graph analysis that combines code attributes and analyzes actual attack paths based on real application architecture, ShiftLeft’s platform scans for attack context and pathways typical of modern applications, across APIs, OSS, internal microservices and first-party business logic code, and then provides detailed guidance on risk remediation within existing development workflows and tooling. ShiftLeft CORE, a unified code security platform, combines the company’s flagship NextGen Static Analysis (NG SAST), Intelligent Software Composition Analysis (SCA), and contextual security training through ShiftLeft Educate to provide developers and application security teams the fastest, most accurate, most relevant, and easiest to use automated application security and code analysis platform.
Backed by Bain Capital Ventures, Mayfield, Thomvest Ventures, and SineWave Ventures, ShiftLeft is based in Santa Clara, CA. To learn how ShiftLeft keeps AppSec in sync with the rapid pace of DevOps, see https://www.shiftleft.io/ .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211117005403/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kubota Vision Inc. Signs Supply and Licensing Agreement with Laboratoires KÔL for Stargardt Disease Treatment Candidate Under Compassionate Use4.5.2026 17:16:00 CEST | Press release
Kubota Vision Inc. (“Kubota Vision”), a wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Minato-ku, Tokyo, Japan) announced signing of a Supply and Licensing Agreement with Laboratoires KÔL (Clermont-Ferrand, France) for the provision of a Stargardt disease (STGD1) treatment candidate under compassionate use authorization. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260414590785/en/ The purpose of this Agreement is for Kubota Vision and KÔL to collaborate on providing “Emixustat” for treatment of Stargardt Disease (STGD1) through compassionate use authorization in France. Kubota Vision will exclusively manufacture and supply Emixustat final products to KÔL and KÔL will have exclusive rights to distribute Emixustat in France under compassionate use access. Ryo Kubota, Chairman, President, and CEO of Kubota Pharmaceutical Holdings, stated, “We are extremely pleased to enter into this Agreement with Labor
Incentive Market Set to Surpass $80B by 2030s — IMA Launches Tools to Help the Industry Keep Pace4.5.2026 16:28:00 CEST | Press release
With combined business spend on loyalty, employee recognition, and channel incentives projected to exceed $80 billion by the 2030s, the incentive industry is entering a period of rapid scale and strategic pressure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260422729016/en/ In response, the Incentive Marketing Association (IMA) launched a new suite of resources designed to help incentive professionals navigate an environment that’s becoming more specialized, fragmented, and central to business performance. “It’s not just more money coming in—it’s more complexity,” said Vince Chiofolo, President of the Incentive & Engagement Solution Providers (IESP). “Buyers are demanding programs that evolve fast, integrate deeply, and feel personal at scale. These new tools were built for that.” IMA’s Suite of Tools Includes: New Industry Report — Inside the Incentive Buyer’s Mind Drawn from insights of 50+ program owners, the report f
Tigo Energy Breaks Global Growth Benchmark; Boosts U.S. Energy Feature in Predict+4.5.2026 15:00:00 CEST | Press release
Advanced energy prediction platform adds real-time energy pricing for North American Independent System Operator (ISO) customers, accelerates meters-connected growth. Tigo Energy, Inc. (NASDAQ: TYGO) (“Tigo” or “Company”), a leading provider of intelligent solar and energy solutions, today announced that the Predict+ platform now offers integrated real-time spot market pricing for ISO customers in the United States. Predict+ provides utilities with deep insights into grid demand, renewable generation, and energy market dynamics, enhancing the precision, scalability, and robustness of energy forecasting to up to 97.5% accuracy through machine learning and artificial intelligence. For energy providers, Predict+ helps streamline operations, reduce volatility, and maximize performance. Predict+ empowers utility operators to adapt to real-world demand challenges when balancing renewable and baseload generation sources, particularly during extreme weather events and market disruptions. On th
Airship Announces 2026 Elevate Customer Experience Award Winners4.5.2026 15:00:00 CEST | Press release
Southwest Airlines, The Economist, and OneFootball among brands recognized at Elevate’26 Customer Experience Summit for setting the standard in mobile-first and AI-centered customer experiences Airship, the mobile-first customer experience company, today announced the winners of the 2026 Elevate Customer Experience Awards. Global brand leaders from The Economist, Southwest Airlines, and OneFootball were among those honored at the Elevate’26 Customer Experience Summit. The Elevate Awards spotlight global companies that have developed exceptional mobile-first customer experiences for their customers, created innovative campaigns, leveraged AI agents to reach new levels of productivity, and achieved real business results. "Evolving mobile-first consumer behaviors and unprecedented advancements in AI are driving a seismic shift that is reshaping how brands interact with their customers," said Brett Caine, CEO, Airship. "The 2026 Elevate Award winners aren’t just adapting, they’re leading t
Alnylam to Present New Analyses at Heart Failure 2026 Underscoring Consistent Clinical Profile of Vutrisiran in ATTR-CM4.5.2026 14:30:00 CEST | Press release
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced it will present new data analyses for vutrisiran in patients with the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) at Heart Failure 2026, a scientific congress of the European Society of Cardiology, taking place May 9-12, 2026, in Barcelona, Spain. ATTR-CM is a heterogeneous and rapidly progressive disease, and patients often present with complex clinical profiles. At Heart Failure 2026, Alnylam will present multiple new analyses from the Phase 3 HELIOS-B study of vutrisiran, which continue to support its use as a first-line treatment for patients with ATTR-CM, and further characterize its clinical profile across patients with a high disease burden, and in the context of concomitant therapies. Vutrisiran is the first and only transthyretin (TTR) silencer for ATTR-CM that delivers rapid knockdown of TTR at the source. Additional analyses being pr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
